~~<i id='98A8253D63'><strike id='98A8253D63'><tt id='98A8253D63'><pre id='98A8253D63'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：entertainment 2025-09-28 01:34:45 - browse：52181

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： STAT Readout Newsletter: Biotech news today

Wikipedia

focus

Wikipedia

entertainment

knowledge

leisure time

MarkLennihan/APAyoungboydiedinatrialforPfizer’sexperimentalgenetherapyforDuchennemusculardystrophy,t

WSS

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Trial using CRISPR to edit HIV out of cells disappoints

Trial using CRISPR to edit HIV out of cells disappoints

STAT Summit: The economic case for universal basic health care

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Covid silver lining: Unprecedented look at human immune system

focus

fashion

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Scientists uncover potential path to treating deadly childhood tumor

Activists slam private health insurers over coverage restrictions

Four alarming medical procedures we’re glad history forgot

As demand for Covid shots wanes, Moderna seeks its next success

Results on Novartis prostate cancer therapy could expand its use

Apple is now the first public company to be valued at $3 trillion

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Summit: How researchers deal with rejection

focus

UnitedHealth, Optum discontinue NaviHealth name

Bird flu in dairy cattle: New measures to control spread to humans

Results on Novartis prostate cancer therapy could expand its use

Results on Novartis prostate cancer therapy could expand its use

Bird flu reported in person exposed to presumably infected cattle

STAT Summit: Ending the crisis of Black deaths in the U.S.

Wikipedia

entertainment

knowledge

leisure time